Physician profile
Alejandro Pruitt
NPI 1568447118
$6,470.26
in general payments reported to CMS, 2019-2025
35 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $203 · 2021: $566 · 2022: $786 · 2023: $1,445 · 2024: $1,714 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.36 | 2020-2025 | |
| Boston Scientific Corporation | $882.33 | 2019-2024 | Habib Endohpb, Axios, Agile Esophageal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $826.07 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $619.62 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $410.52 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $228.77 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $222.06 | 2024-2025 | Omvoh |
| Genzyme Corporation | $204.36 | 2023-2025 | |
| Gilead Sciences, INC. | $195.58 | 2021-2025 | |
| Celgene Corporation | $171.40 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $168.45 | 2023-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $159.94 | 2021-2023 | |
| Pfizer INC. | $115.65 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $105.21 | 2024 | |
| Olympus America INC. | $66.17 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $59.18 | 2021-2024 | |
| Ardelyx, INC. | $57.18 | 2022-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $53.48 | 2025 | Rezdiffra |
| Celltrion USA INC. | $38.21 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $36.18 | 2023-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $32.78 | 2024 | Dificid |
| Allergan, INC. | $23.98 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.61 | 2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $18.93 | 2025 | Dupixent |
| Novo Nordisk INC | $18.67 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $18.09 | 2020 | |
| Medtronic, INC. | $17.48 | 2022 | |
| Vivus LLC | $17.22 | 2022 | |
| Evoke Pharma, INC. | $15.67 | 2025 | |
| Ironwood Pharmaceuticals, INC | $14.85 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $14.80 | 2025 | Forceps |
| Eisai INC. | $14.74 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.97 | 2024 | Iqirvo |
| Amgen INC. | $12.75 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,308.34 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Pruitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.